Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis
- 1 June 2018
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 59, 86-96
Abstract
No abstract availableKeywords
Funding Information
- Research Support Foundation, Vaduz, Fürstentum Liechtenstein
This publication has 21 references indexed in Scilit:
- The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma modelInternational Immunopharmacology, 2016
- In-situ tumor vaccination: Bringing the fight to the tumorHuman Vaccines & Immunotherapeutics, 2015
- Turning Tumors into Vaccines: Co-opting the Innate Immune SystemImmunity, 2013
- Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonistsNature Medicine, 2007
- Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNAImmunology Letters, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFNJournal of Experimental Medicine, 2004
- TNF-α Induces Phosphorylation of p47phox in Human Neutrophils: Partial Phosphorylation of p47phox Is a Common Event of Priming of Human Neutrophils by TNF-α and Granulocyte-Macrophage Colony-Stimulating FactorThe Journal of Immunology, 2003
- Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimodCellular Immunology, 2002
- THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELASThe American Journal of the Medical Sciences, 1893